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Late secondary procedures have been the necessary baggage
that endovascular operators and our patients were willing to
shoulder for the putative benefits of lower morbidity, mortality,
and early recovery after endovascular aortic aneurysm repair
(EVAR). The study by Giles et al from the Harvard Medical
School’s Health Care Policy group has examined this important
outcome measure as it relates to late survival. Two points are
worth noting. First, late complications are an equal opportunity
hazard for both endovascular and open repairs, albeit the types
and magnitudes of these complications may be different. Sec-
ond, these complications and their treatments negatively impact
survival of these patients.
Early estimates of the cumulative risk of secondary procedures
after EVAR ranged from 10% to 15% per year. This risk was
progressive and did not plateau over time. However, it is encour-
aging to see that these rates may have been overestimated based on
current Medicare data, even with the inclusion of hospital admis-
sions that did not involve an intervention. Althoughmortality afterstudies, EVAR mortality has been shown to be even lower by at
least half those figures. Yet, it is somewhat sobering that all of these
gains made after the index repair are completely eliminated by a
secondary intervention, whose mortality rates can exceed 10%.
Furthermore, contrary to what had been suggested earlier in this
decade, the presence of an endograft does not appear to be
protective if the therapy fails and the aneurysm ruptures. This study
may serve as the most compelling evidence to date for why one
needs to do it right the first time, because the stakes are so much
higher next time.
Nearly 10 years ago when endovascular repair was gaining
acceptance as a viable first-line treatment for aortic aneurysms in
the United States, economic considerations were intensely studied
given the high cost of these devices compared with conventional
surgical grafts. Now that the “physiologic cost” of late failures has
been defined, the next step is to compare the economic costs of
repeat interventions in this therapy, which will be the next impor-
tant piece in defining the full fiscal impact of the initial repair and itsopen repair has been consistently 3% in most of the prospective subsequent maintenance.
